Copan stakes its future on domestic production growth
Subscribe to our free newsletter today to keep up to date with the latest manufacturing news.
Copan Diagnostics is committing more than $7 million to expand its US manufacturing presence in California and Puerto Rico, aiming to strengthen production of respiratory and urine specimen collection kits and to localize critical supply chains.
The funding is earmarked for expanding facilities, upgrading quality control systems, introducing new manufacturing processes, and increasing US sourcing of reagents and components. Among the projects is a $1 million investment into US production of UriSponge®, Copan’s novel urine collection device. Construction is underway, with operations expected to begin in early 2026.
A trends driven move in manufacturing
Copan’s decision is consistent with a broader wave of reshoring and nearshoring in advanced manufacturing sectors. In 2025, a strong majority of manufacturing and supply chain leaders cited onshoring as a priority in response to persistent supply chain volatility. At the same time, firms are navigating the tension between resilience and cost efficiency, a rebalancing that Deloitte describes as central to post‑pandemic supply chain strategies. The revival of US industrial capacity has gained momentum across sectors, driven by both geopolitical risk and shifting trade policies.
In diagnostics and life sciences, securing a dependable domestic supply of critical components such as swabs, transport media, reagents, and collection devices, has become a strategic priority. Copan’s expansion responds directly to this need. By localizing manufacturing, the company reduces exposure to international shipping delays, tariff fluctuations, and the disruptions that exposed global supply networks during the pandemic.
Impacts on supply chains and local ecosystems
Increasing domestic production yields several downstream effects. First, it enhances resilience. Local facilities shorten lead times and buffer against global shocks, which is a central objective of modern supply chain design. Second, it drives higher value deeper in the supply chain, US suppliers of reagents, plastics, and lab components stand to benefit from new demand. Copan is allocating $1 million specifically for increased US sourcing. Third, the move may stimulate job creation and capabilities development in regions where the facilities operate. Copan already employs over 450 staff in its US operations.
In aggregate, these shifts strengthen the case for a more distributed, domestically anchored manufacturing footprint in diagnostics and adjacent sectors.
Challenges and risks in execution
Execution, however, will not be frictionless. The US manufacturing sector continues to contend with tight labor markets and difficulty attracting and retaining skilled technical workers, factors that appear in surveys as top concerns for industrial firms. Inflationary pressures on raw materials and energy could erode margins. Furthermore, aligning quality systems and regulatory compliance in newly scaled operations requires careful oversight in highly regulated sectors like diagnostics.
Copan’s establishment of a centralized quality assurance laboratory as part of the expansion is a deliberate move to manage these risks. It suggests the firm is anticipating complexities in standardization, oversight, and scaling.
On the strategic front, the company must calibrate investments so that capacity aligns with market demand. Overexpansion risks underutilization; underinvestment leaves it vulnerable to the very supply chain risks the expansion aims to mitigate.
In fast‑evolving diagnostics markets, incremental advantages in lead time, supply stability, and regulatory clarity can translate into competitive edge. Copan’s investment signals more than facility growth, it reflects a bet on reshaping its operating model around domestic control and responsiveness.
Let me know if you’d like a version with a different slant (e.g. policy focus, competitive comparisons, regional emphasis) or want to adjust word count.
Sources: